查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889428

微生物組療法市場預測至2032年：按治療方法類型、目標領域、技術、應用、最終用戶和地區分類的全球分析

Microbiome Therapies Market Forecasts to 2032 - Global Analysis By Therapy Type, Target Area, Technology, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，2025 年全球微生物組療法市場價值將達到 32 億美元，預計到 2032 年將達到 146 億美元。

預計在預測期內，微生物組療法將以24.2%的複合年成長率高速成長。微生物組療法是治療方法。這些療法利用益生菌、基因改造細菌、微生物移植或標靶微生物代謝物來治療與腸道菌叢失衡相關的疾病。其應用範圍不斷擴大，涵蓋胃腸道疾病、代謝性疾病、免疫調節、腫瘤和神經發育障礙等領域。先進的分析技術能夠精確調控微生物組的相互作用，從而發展出與傳統藥物相比副作用較少的個人化治療策略。

根據 Strategic Revenue Insights 的一項消費者調查，人們對腸道健康的日益關注推動了微生物組療法需求的每年 20% 的成長，其中 62% 的受訪者優先考慮益生菌以增強免疫和代謝功能。

對個人化醫療的需求日益成長

推動成長的主要動力是對個人化醫療日益成長的需求。人工智慧和基因測序等先進技術正在協助開發針對個體獨特微生物組成的客製化微生物組療法。這種從通用治療模式轉變為個人化治療的轉變將顯著提高癌症、代謝紊亂和自體免疫疾病等複雜疾病的治療效果。對精準醫療的關注是市場發展的關鍵驅動力，有望改善患者預後，並刺激該領域的投資和創新。

複雜的監管核准流程

複雜且不斷變化的全球監管標準給市場帶來了巨大挑戰。儘管美國FDA已為生物治療產品（LBP）制定了明確的核准途徑，但歐洲和亞太地區的監管機構仍在製定各自的指導方針。這種缺乏協調性的情況為製造商帶來了不確定性，導致產品核可延遲和研發成本顯著增加。對於在多個國際市場營運的公司而言，如何應對這種分散且往往不穩定的監管環境仍然是一項重大限制。

代謝疾病的新應用

代謝疾病領域的新興應用前景廣闊，蘊藏著巨大的成長機會。目前，研究正不斷深入，探討腸道菌叢對肥胖、第二型糖尿病和非酒精性脂肪肝等疾病的直接影響。諸如諾和諾德基金會的「微生物組健康舉措」等重大舉措，正大力投資開發能夠調節腸道菌叢以改善心血管代謝健康的新型治療方法。這種認知的加深，為超越傳統胃腸道適應症的治療方法研發開闢了廣闊的新天地。

關於活微生物產品的安全問題

活性微生物產品的潛在安全隱憂構成重大威脅。與傳統藥物不同，活性微生物產品含有活菌，這給產品的穩定性、與患者獨特微生物群的相互作用以及傳播抗生素抗藥性基因的風險等方面帶來了獨特的挑戰。此外，免疫力缺乏的患者也存在理論上的感染風險。這些隱患需要嚴格的長期安全監測和複雜的生產控制，這可能會阻礙投資並使監管核准複雜化，從而限制其在市場上的廣泛應用。

新冠疫情的影響：

疫情初期擾亂了臨床試驗、生產活動和供應鏈，延緩了多個微生物組候選產品的研發進程。然而，人們對免疫韌性和宿主-微生物相互作用日益成長的興趣促使疫情後投資回升，研究加速推進。數位化臨床監測的廣泛應用也為試驗活動的恢復提供了支持。消費者和臨床機構對微生物健康意識的提高，增強了他們對微生物組解決方案的興趣，最終推動該領域在後疫情時代實現了更快成長，儘管初期面臨一些營運挑戰。

預計在預測期內，生物製劑治療產品（LBP）細分市場將佔據最大的市場佔有率。

由於其廣泛的治療適應症、高額的臨床投入以及微生物組調節益處的有力證據，生物治療產品（LBP）領域預計將在預測期內佔據最大的市場佔有率。 LBP 可針對從胃腸道疾病到免疫和代謝紊亂等多種病症，具有廣泛的應用潛力。菌株設計、製劑穩定性以及精準給藥技術的進步進一步鞏固了其優勢。生物技術公司和製藥公司之間日益密切的合作也進一步強化了主導地位。

預計在預測期內，腸道微生物組細分市場將呈現最高的複合年成長率。

預計在預測期內，腸道微生物組領域將呈現最高的成長速度。大量研究顯示腸道菌叢組成與全身免疫、代謝調節和神經系統健康密切相關，這為上述預測提供了強力支撐。強大的臨床研發管線、先進的定序技術以及診斷整合的進步正在加速治療方法的發展。隨著個人化營養、代謝和免疫調節療法的擴展，以腸道為中心的干涉措施正蓬勃發展。其廣泛的疾病適用性和快速的科學檢驗，使該領域成為微生物組治療領域中成長最快的方向。

佔比最大的地區：

由於生物技術投資不斷成長、臨床研究基礎設施不斷完善以及消化器官系統和代謝疾病的高發，亞太地區預計將在預測期內佔據最大的市場佔有率。中國、日本、韓國和新加坡等國家對微生物組創新表現出強而有力的監管支持。消費者意識的提高、精準醫療舉措的擴展以及先進定序技術的出現，進一步推動了相關技術的應用。強大的生產能力和政府支持的研發項目鞏固了亞太地區的市場主導地位。

預計年複合成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於強勁的創業投資流入、先進的臨床試驗生態系統以及創新療法快速的商業化途徑。美國憑藉其前沿的微生物組研究、精準醫療的高普及率以及生物技術公司、學術機構和製藥公司之間的積極合作，處於主導地位。對標靶治療的需求不斷成長、FDA的支持性舉措以及多組體學的日益融合將進一步推動成長，使北美成為成長最快的市場。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球微生物組療法市場（依治療方法類型分類）

  • 生物醫學產品（LBPs）
  • 糞便微生物移植（FMT）
  • 人工微生物群落
  • 新一代益生菌
  • 益生元和後生元
  • 基於噬菌體的治療方法

6. 全球微生物組療法市場（依目標區域分類）

  • 腸道微生物組
  • 口腔微生物組
  • 皮膚微生物組
  • 陰道微生物組
  • 呼吸道微生物組
  • 神經和免疫微生物組

7. 全球微生物組療法市場（依技術分類）

  • 基因組學和定序技術
  • 計算建模與人工智慧
  • 合成生物學平台
  • 精準微生物組編輯
  • 試管內微生物組培養
  • 基於體學的分析工具

8. 全球微生物組療法市場（按應用分類）

  • 消化系統疾病
  • 代謝性疾病
  • 免疫學/自體免疫疾病
  • 皮膚病
  • 精神健康與神經退化性疾病
  • 感染疾病

9. 全球微生物組療法市場（以最終用戶分類）

  • 製藥公司
  • 生技公司
  • 研究和臨床試驗機構
  • 醫院和治療中心
  • 合約研究組織和學術機構
  • 專業健康診所

10. 全球微生物組療法市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • Vedanta Biosciences
  • Finch Therapeutics
  • Synthetic Biologics
  • 4D Pharma
  • BiomeBank
  • Evelo Biosciences
  • Enterome
  • Rebiotix（Ferring）
  • Takeda
  • Johnson &Johnson
  • Novartis
  • GSK
  • Pfizer
  • Roche
  • Merck &Co.
Product Code: SMRC32802

According to Stratistics MRC, the Global Microbiome Therapies Market is accounted for $3.2 billion in 2025 and is expected to reach $14.6 billion by 2032 growing at a CAGR of 24.2% during the forecast period. Microbiome Therapies are treatments designed to modify or restore the microbial ecosystems within the human body to improve health outcomes. These therapies utilize probiotics, engineered bacteria, microbiota transplants, or targeted microbial metabolites to address diseases linked to dysbiosis. They play an expanding role in gastrointestinal disorders, metabolic diseases, immune modulation, oncology, and neurodevelopmental conditions. Advanced analytics enable precision modulation of microbiome interactions, creating personalized therapeutic strategies with fewer side effects compared to conventional drugs.

According to a Strategic Revenue Insights consumer survey, rising awareness of gut health drives 20% annual increase in demand for microbiome therapies, with 62% of respondents prioritizing probiotics for immune and metabolic support.

Market Dynamics:

Driver:

Increasing demand for personalized medicine

Growth is primarily fueled by the increasing demand for personalized medicine. Advanced technologies like artificial intelligence and genomic sequencing are enabling the development of microbiome therapies tailored to an individual's unique microbial composition. This shift from a universal treatment model to a personalized approach significantly enhances therapeutic efficacy for complex conditions such as cancer, metabolic disorders, and autoimmune diseases. This focus on precision health is a key market driver, promising better patient outcomes and driving investment and innovation in the sector.

Restraint:

Complex regulatory pathways for approval

The market faces significant challenges from complex and evolving global regulatory standards. While the U.S. FDA has established a defined pathway for Live Biotherapeutic Products (LBPs), regulatory agencies in Europe and Asia-Pacific are still refining their own guidelines. This lack of harmonization creates uncertainty for manufacturers, leading to extended product approval timelines and significantly higher development costs. Navigating this fragmented and often unsettled regulatory landscape remains a major restraint for companies operating across different international markets.

Opportunity:

Emerging applications in metabolic disorders

Emerging applications in metabolic disorders represent a significant growth opportunity. There is increasing research into the gut microbiome's direct influence on conditions like obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Major initiatives, such as the Novo Nordisk Foundation's Microbiome Health Initiative, are investing heavily to develop novel therapies that modulate the gut microbiota to improve cardiometabolic health. This expanding understanding opens a vast new frontier for therapeutic development beyond traditional gastrointestinal indications.

Threat:

Safety concerns with live microbial products

A key threat involves potential safety concerns associated with live microbial products. Unlike traditional drugs, LBPs contain living organisms, raising unique challenges regarding their stability, interaction with a patient's native microbiome, and the risk of transmitting antibiotic resistance genes. There is also a theoretical risk of infections in immunocompromised patients. These concerns necessitate rigorous long-term safety monitoring and complex manufacturing controls, which can deter investment and complicate regulatory approval, potentially limiting widespread market adoption.

Covid-19 Impact:

The pandemic initially disrupted clinical trials, manufacturing activities, and supply chains, slowing development timelines for several microbiome candidates. However, rising interest in immune resilience and host-microbe interactions stimulated renewed investment and accelerated research post-pandemic. Increased adoption of digital clinical monitoring supported recovery of trial activity. Heightened awareness of microbial health strengthened consumer and clinical interest in microbiome solutions, ultimately positioning the sector for faster growth in the post-COVID landscape despite early operational setbacks.

The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period

The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, owing to their broad therapeutic applicability, high clinical investment, and strong evidence demonstrating microbiome modulation benefits. LBPs target diverse conditions ranging from gastrointestinal disorders to immunological and metabolic diseases, creating wide adoption potential. Advances in strain engineering, formulation stability, and precision dosing reinforce their dominance. Growing partnerships between biotech firms and pharmaceutical companies further solidify the segment's leadership position.

The gut microbiome segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gut microbiome segment is predicted to witness the highest growth rate, reinforced by extensive research linking gut microbial composition to systemic immunity, metabolic regulation, and neurological health. Strong clinical pipelines, enhanced sequencing technologies, and rising diagnostic integration accelerate therapeutic development. As personalized nutrition, metabolic therapies, and immunomodulatory treatments expand, gut-focused interventions gain momentum. Broad disease applicability and rapid scientific validation position this segment as the fastest-advancing domain within microbiome therapeutics.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, ascribed to increasing biotech investments, expanding clinical research infrastructure, and high prevalence of gastrointestinal and metabolic disorders. Countries such as China, Japan, South Korea, and Singapore exhibit strong regulatory support for microbiome innovation. Rising consumer awareness, growing precision-medicine initiatives, and the presence of advanced sequencing capabilities further accelerate adoption. Robust manufacturing capacity and government-backed R&D programs solidify APAC's dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with strong venture capital influx, advanced clinical trial ecosystems, and rapid commercialization pathways for innovative therapeutics. The U.S. leads with cutting-edge microbiome research, high adoption of precision medicine, and active collaborations between biotech firms, academic centers, and pharmaceutical companies. Growing demand for targeted therapies, supportive FDA initiatives, and expanding multi-omics integration further propel growth, positioning North America as the fastest-expanding market.

Key players in the market

Some of the key players in Microbiome Therapies Market include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, Finch Therapeutics, Synthetic Biologics, 4D Pharma, BiomeBank, Evelo Biosciences, Enterome, Rebiotix (Ferring), Takeda, Johnson & Johnson, Novartis, GSK, Pfizer, Roche and Merck & Co.

Key Developments:

In November 2025, Vedanta progressed Phase II trials of VE303 for recurrent C. difficile infection, leveraging defined bacterial consortia to deliver standardized microbiome therapeutics with improved safety and efficacy profiles.

In October 2025, Seres advanced commercialization of VOWST(TM), its FDA-approved microbiome therapeutic for recurrent C. difficile infection, expanding distribution partnerships and initiating new clinical trials for ulcerative colitis and oncology indications.

In September 2025, Ferring scaled production of REBYOTA(TM), the first FDA-approved fecal microbiota therapy, expanding access in North America and Europe while investing in next-generation microbiome-based therapeutics for gastrointestinal disorders.

Therapy Types Covered:

  • Live Biotherapeutic Products (LBPs)
  • Fecal Microbiota Transplantation (FMT)
  • Engineered Microbial Consortia
  • Next-Generation Probiotics
  • Prebiotics & Postbiotics
  • Phage-Based Therapies

Target Areas Covered:

  • Gut Microbiome
  • Oral Microbiome
  • Skin Microbiome
  • Vaginal Microbiome
  • Respiratory Microbiome
  • Neural & Immune Microbiome

Technologies Covered:

  • Genomics & Sequencing Technologies
  • Computational Modeling & AI
  • Synthetic Biology Platforms
  • Precision Microbiome Editing
  • In Vitro Microbiome Culturing
  • Omics-Based Profiling Tools

Applications Covered:

  • Gastrointestinal Disorders
  • Metabolic Diseases
  • Immune & Autoimmune Disorders
  • Skin Disorders
  • Mental Health & Neurodegeneration
  • Infectious Diseases

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research & Clinical Labs
  • Hospitals & Treatment Centers
  • CROs & Academic Institutions
  • Specialty Wellness Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microbiome Therapies Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Live Biotherapeutic Products (LBPs)
  • 5.3 Fecal Microbiota Transplantation (FMT)
  • 5.4 Engineered Microbial Consortia
  • 5.5 Next-Generation Probiotics
  • 5.6 Prebiotics & Postbiotics
  • 5.7 Phage-Based Therapies

6 Global Microbiome Therapies Market, By Target Area

  • 6.1 Introduction
  • 6.2 Gut Microbiome
  • 6.3 Oral Microbiome
  • 6.4 Skin Microbiome
  • 6.5 Vaginal Microbiome
  • 6.6 Respiratory Microbiome
  • 6.7 Neural & Immune Microbiome

7 Global Microbiome Therapies Market, By Technology

  • 7.1 Introduction
  • 7.2 Genomics & Sequencing Technologies
  • 7.3 Computational Modeling & AI
  • 7.4 Synthetic Biology Platforms
  • 7.5 Precision Microbiome Editing
  • 7.6 In Vitro Microbiome Culturing
  • 7.7 Omics-Based Profiling Tools

8 Global Microbiome Therapies Market, By Application

  • 8.1 Introduction
  • 8.2 Gastrointestinal Disorders
  • 8.3 Metabolic Diseases
  • 8.4 Immune & Autoimmune Disorders
  • 8.5 Skin Disorders
  • 8.6 Mental Health & Neurodegeneration
  • 8.7 Infectious Diseases

9 Global Microbiome Therapies Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biotechnology Firms
  • 9.4 Research & Clinical Labs
  • 9.5 Hospitals & Treatment Centers
  • 9.6 CROs & Academic Institutions
  • 9.7 Specialty Wellness Clinics

10 Global Microbiome Therapies Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Seres Therapeutics
  • 12.2 Ferring Pharmaceuticals
  • 12.3 Vedanta Biosciences
  • 12.4 Finch Therapeutics
  • 12.5 Synthetic Biologics
  • 12.6 4D Pharma
  • 12.7 BiomeBank
  • 12.8 Evelo Biosciences
  • 12.9 Enterome
  • 12.10 Rebiotix (Ferring)
  • 12.11 Takeda
  • 12.12 Johnson & Johnson
  • 12.13 Novartis
  • 12.14 GSK
  • 12.15 Pfizer
  • 12.16 Roche
  • 12.17 Merck & Co.

List of Tables

  • Table 1 Global Microbiome Therapies Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Microbiome Therapies Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Microbiome Therapies Market Outlook, By Live Biotherapeutic Products (LBPs) (2024-2032) ($MN)
  • Table 4 Global Microbiome Therapies Market Outlook, By Fecal Microbiota Transplantation (FMT) (2024-2032) ($MN)
  • Table 5 Global Microbiome Therapies Market Outlook, By Engineered Microbial Consortia (2024-2032) ($MN)
  • Table 6 Global Microbiome Therapies Market Outlook, By Next-Generation Probiotics (2024-2032) ($MN)
  • Table 7 Global Microbiome Therapies Market Outlook, By Prebiotics & Postbiotics (2024-2032) ($MN)
  • Table 8 Global Microbiome Therapies Market Outlook, By Phage-Based Therapies (2024-2032) ($MN)
  • Table 9 Global Microbiome Therapies Market Outlook, By Target Area (2024-2032) ($MN)
  • Table 10 Global Microbiome Therapies Market Outlook, By Gut Microbiome (2024-2032) ($MN)
  • Table 11 Global Microbiome Therapies Market Outlook, By Oral Microbiome (2024-2032) ($MN)
  • Table 12 Global Microbiome Therapies Market Outlook, By Skin Microbiome (2024-2032) ($MN)
  • Table 13 Global Microbiome Therapies Market Outlook, By Vaginal Microbiome (2024-2032) ($MN)
  • Table 14 Global Microbiome Therapies Market Outlook, By Respiratory Microbiome (2024-2032) ($MN)
  • Table 15 Global Microbiome Therapies Market Outlook, By Neural & Immune Microbiome (2024-2032) ($MN)
  • Table 16 Global Microbiome Therapies Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Microbiome Therapies Market Outlook, By Genomics & Sequencing Technologies (2024-2032) ($MN)
  • Table 18 Global Microbiome Therapies Market Outlook, By Computational Modeling & AI (2024-2032) ($MN)
  • Table 19 Global Microbiome Therapies Market Outlook, By Synthetic Biology Platforms (2024-2032) ($MN)
  • Table 20 Global Microbiome Therapies Market Outlook, By Precision Microbiome Editing (2024-2032) ($MN)
  • Table 21 Global Microbiome Therapies Market Outlook, By In Vitro Microbiome Culturing (2024-2032) ($MN)
  • Table 22 Global Microbiome Therapies Market Outlook, By Omics-Based Profiling Tools (2024-2032) ($MN)
  • Table 23 Global Microbiome Therapies Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Microbiome Therapies Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 25 Global Microbiome Therapies Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 26 Global Microbiome Therapies Market Outlook, By Immune & Autoimmune Disorders (2024-2032) ($MN)
  • Table 27 Global Microbiome Therapies Market Outlook, By Skin Disorders (2024-2032) ($MN)
  • Table 28 Global Microbiome Therapies Market Outlook, By Mental Health & Neurodegeneration (2024-2032) ($MN)
  • Table 29 Global Microbiome Therapies Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 30 Global Microbiome Therapies Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Microbiome Therapies Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 32 Global Microbiome Therapies Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 33 Global Microbiome Therapies Market Outlook, By Research & Clinical Labs (2024-2032) ($MN)
  • Table 34 Global Microbiome Therapies Market Outlook, By Hospitals & Treatment Centers (2024-2032) ($MN)
  • Table 35 Global Microbiome Therapies Market Outlook, By CROs & Academic Institutions (2024-2032) ($MN)
  • Table 36 Global Microbiome Therapies Market Outlook, By Specialty Wellness Clinics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.